Related Experiment Videos
Biologic and immunologic therapy of ovarian cancer
1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Abstract:
Conventional cytotoxic chemotherapy fails to cure the majority of patients with advanced-stage ovarian cancer, in spite of encouraging initial antitumor responses. With the emergence of drug resistance in refractory tumors, new biologic and immunologic treatment strategies are needed. Small-volume residual peritoneal disease remains an attractive target for therapeutic trials; however, even in this optimal circumstance, few regimens have yet achieved a high frequency of pathologically confirmed complete remissions. Considerable progress has been made in understanding the impact of growth factors and their receptors on tumor growth regulation and modulation of response to chemotherapy. Better characterization of the antigens recognized by monoclonal antibodies, as well as sequencing of the antibodies themselves, has permitted the rational design of therapeutic reagents that take full advantage of molecular biology techniques for production and conjugation. Important limitations of preclinical models for prediction of host toxicity are recognized, and the reasons for treatment failure in situ, as well as strategies to prevent serious dose-limiting toxicities, are being explored. Further developments in cytokine biology, adoptive cellular therapy, monoclonal antibody conjugation, and molecular biology will continue to provide a growing array of reagents for critical evaluation.
Insights
New biologic and immunologic treatments are needed for advanced ovarian cancer due to chemotherapy resistance. Research focuses on novel strategies targeting residual disease and improving therapeutic reagent design for better patient outcomes.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Advanced-stage ovarian cancer often develops chemotherapy resistance, limiting treatment efficacy.
- Residual peritoneal disease presents a therapeutic challenge, with few regimens achieving complete remission.
- Understanding growth factors, their receptors, and tumor antigens is crucial for developing new treatments.
Purpose of the Study:
- To explore novel biologic and immunologic treatment strategies for advanced ovarian cancer.
- To address the challenge of drug resistance and improve complete remission rates.
- To leverage advancements in molecular biology for designing targeted therapeutic reagents.
Main Methods:
- Investigating the role of growth factors and their receptors in tumor growth and chemotherapy response.
- Characterizing tumor antigens for the development of monoclonal antibody-based therapies.
- Utilizing molecular biology techniques for the production and conjugation of therapeutic reagents.
Main Results:
- Progress in understanding tumor biology and antigen recognition.
- Development of rational designs for therapeutic reagents using molecular biology.
- Recognition of limitations in preclinical models for predicting toxicity.
Conclusions:
- New biologic and immunologic strategies are essential for overcoming chemotherapy resistance in ovarian cancer.
- Advancements in monoclonal antibody technology and molecular biology offer promising therapeutic avenues.
- Further research is needed to optimize treatment strategies and prevent dose-limiting toxicities.